Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.
复制标题

DOI:
10.1126/science.abd7728
复制
发表时间:
2020-12-04
期刊:
Science (New York, N.Y.)
影响因子:
--
通讯作者:
Cordon-Cardo C
Cordon-Cardo C
中科院分区:
其他
文献类型:
--
作者:
Wajnberg A;Amanat F;Firpo A;Altman DR;Bailey MJ;Mansour M;McMahon M;Meade P;Mendu DR;Muellers K;Stadlbauer D;Stone K;Strohmeier S;Simon V;Aberg J;Reich DL;Krammer F;Cordon-Cardo C

文献摘要

参考文献

被引文献

相似文献

随着全球每日 COVID-19 病例数量持续增加,针对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的体液免疫反应的性质仍不确定。瓦金伯格等人。使用了超过 30,000 名具有轻度至中度 COVID-19 症状的感染者的队列来确定抗 SARS-CoV-2 抗体反应的稳健性和寿命。他们发现,针对 SARS-CoV-2 刺突蛋白的中和抗体滴度在感染后持续至少 5 个月。尽管需要对这一群体进行持续监测,以确认这种反应的持续时间和效力,但这些初步结果表明,再次感染的可能性可能低于目前担心的水平。科学,本期第 14 页。 1227 轻度至中度 SARS-CoV-2 感染后产生的抗体具有中和作用,并且在至少 5 个月内相对稳定。严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 已引起全球大流行,造成数百万人感染,超过 100 万人死亡。关于抗体对病毒反应的稳健性、功能性和寿命的问题仍未得到解答。在这里,根据在纽约市西奈山卫生系统筛查的 30,082 人的数据集,我们报告说,绝大多数患有轻度至中度 COVID-19 的感染者都经历了针对病毒刺突蛋白的强烈免疫球蛋白 G 抗体反应。我们还表明,滴度在至少约 5 个月的时间内相对稳定,并且抗刺突结合滴度与真正的 SARS-CoV-2 的中和显着相关。我们的数据表明,超过 90% 的血清转化者会产生可检测到的中和抗体反应。这些滴度在感染后几个月内保持相对稳定。
As the number of daily COVID-19 cases continues to mount worldwide, the nature of the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains uncertain. Wajnberg et al. used a cohort of more than 30,000 infected individuals with mild to moderate COVID-19 symptoms to determine the robustness and longevity of the anti–SARS-CoV-2 antibody response. They found that neutralizing antibody titers against the SARS-CoV-2 spike protein persisted for at least 5 months after infection. Although continued monitoring of this cohort will be needed to confirm the longevity and potency of this response, these preliminary results suggest that the chance of reinfection may be lower than is currently feared. Science, this issue p. 1227 Antibodies generated after mild to moderate SARS-CoV-2 infection are neutralizing and relatively stable for at least 5 months. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with millions infected and more than 1 million fatalities. Questions regarding the robustness, functionality, and longevity of the antibody response to the virus remain unanswered. Here, on the basis of a dataset of 30,082 individuals screened at Mount Sinai Health System in New York City, we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust immunoglobulin G antibody responses against the viral spike protein. We also show that titers are relatively stable for at least a period of about 5 months and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2. Our data suggest that more than 90% of seroconverters make detectable neutralizing antibody responses. These titers remain relatively stable for several months after infection.
DOI: 10.1038/s41591-020-0897-1
发表时间: 2020-04-29
期刊: NATURE MEDICINE
影响因子: 82.9
作者:
Long, Quan-Xin;Liu, Bai-Zhong;Huang, Ai-Long
通讯作者: Huang, Ai-Long
DOI: 10.1016/s2666-5247(20)30120-8
发表时间: 2020-11
期刊: The Lancet. Microbe
影响因子: --
作者:
Wajnberg A;Mansour M;Leven E;Bouvier NM;Patel G;Firpo-Betancourt A;Mendu R;Jhang J;Arinsburg S;Gitman M;Houldsworth J;Sordillo E;Paniz-Mondolfi A;Baine I;Simon V;Aberg J;Krammer F;Reich D;Cordon-Cardo C
通讯作者: Cordon-Cardo C
DOI: 10.1038/s41591-020-0913-5
发表时间: 2020-07
期刊: Nature medicine
影响因子: 82.9
作者:
Amanat F;Stadlbauer D;Strohmeier S;Nguyen THO;Chromikova V;McMahon M;Jiang K;Arunkumar GA;Jurczyszak D;Polanco J;Bermudez-Gonzalez M;Kleiner G;Aydillo T;Miorin L;Fierer DS;Lugo LA;Kojic EM;Stoever J;Liu STH;Cunningham-Rundles C;Felgner PL;Moran T;García-Sastre A;Caplivski D;Cheng AC;Kedzierska K;Vapalahti O;Hepojoki JM;Simon V;Krammer F
通讯作者: Krammer F
DOI: 10.1126/science.abc6284
发表时间: 2020-08-14
期刊: SCIENCE
影响因子: 56.9
作者:
Yu, Jingyou;Tostanoski, Lisa H.;Barouch, Dan H.
通讯作者: Barouch, Dan H.
DOI: 10.1080/22221751.2020.1791738
发表时间: 2020-01-01
影响因子: 13.2
作者:
Liu, Li;To, Kelvin Kai-Wang;Chen, Zhiwei
通讯作者: Chen, Zhiwei